| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/13/2005 | WO2005003352A1 Method of judging responsivenesses to taxans |
| 01/13/2005 | WO2005003329A1 Novel galactooligosaccharide composition and the preparation thereof |
| 01/13/2005 | WO2005003325A2 Inhibition of viral pathogenesis |
| 01/13/2005 | WO2005003301A2 Methods, compositions, and kits for predicting the effect of compounds on hot flash symptoms |
| 01/13/2005 | WO2005003292A2 Composition and method for self-assembly and mineralization of peptide amphiphiles |
| 01/13/2005 | WO2005003150A2 Compositions and methods for use of a protease inhibitor and adenosine for preventing organ ischemia and reperfusion injury |
| 01/13/2005 | WO2005003149A1 Process for the preparation of finasteride form i |
| 01/13/2005 | WO2005003146A1 The c-glycosylisoflavones having alkylaminoalkoxyl substituent, the preparation and the use of the same |
| 01/13/2005 | WO2005003145A1 Shanzhuyu extract and uses thereof |
| 01/13/2005 | WO2005003137A1 Salinosporamides and methods for use thereof |
| 01/13/2005 | WO2005003135A1 Phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor |
| 01/13/2005 | WO2005003130A1 Novel pyrrolodihydroisoquinolines useful in the treatment of cancer |
| 01/13/2005 | WO2005003129A1 Pyrrolodihydroisoquinolines as pde10 inhibitors |
| 01/13/2005 | WO2005003122A1 5ht4-antagonistic 4-(aminomethyl)-piperidine benzamides |
| 01/13/2005 | WO2005003117A1 Imidazole derivatives iii |
| 01/13/2005 | WO2005003115A1 Thiophene amino acid derivatives, process for preparing them and pharmaceutical compositions containing them |
| 01/13/2005 | WO2005003114A1 5-fluoro-thiopen-compounds,the process for their preparation,the pharmaceutical compositions containing them and their use as metallopotenases inhibitors |
| 01/13/2005 | WO2005003111A1 Preventive or remedy for viral conjunctivitis |
| 01/13/2005 | WO2005003106A1 Macrocyclic compounds having aspartic protease inhibiting activity and pharmaceutical uses thereof |
| 01/13/2005 | WO2005003102A1 Methods of preparation of dehydro-diketopiperazines in liquid phase or of solid supported phase |
| 01/13/2005 | WO2005003100A2 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis |
| 01/13/2005 | WO2005003094A1 Diarylmethyl derivatives as potassium channel modulators |
| 01/13/2005 | WO2005003090A1 1- (alkylaminoalkyl-pyrolidin-/piperidinyl) -2, 2-diphenylacetamide derivatives as muscarinic receptor antagonists |
| 01/13/2005 | WO2005003087A2 Oxazole derivatives as antibacterial agents |
| 01/13/2005 | WO2005003085A2 Tajixanthone hydrate and tajixanthone hydrate derivatives, biological activities thereof, and use thereof |
| 01/13/2005 | WO2005003065A2 Sulfonamide substituted imidazoquinolines |
| 01/13/2005 | WO2005003064A2 Sulfonamide substituted imidazoquinolines |
| 01/13/2005 | WO2005002673A1 Raf kinase inhibitors |
| 01/13/2005 | WO2005002672A2 Sirt1 modulators for manipulating cells/organism lifespan/stress response |
| 01/13/2005 | WO2005002629A1 Combination therapy of oxaliplatin and radioactively doped particles treating cancer |
| 01/13/2005 | WO2005002625A2 In-situ gelling drug delivery system |
| 01/13/2005 | WO2005002624A1 Prolyl oligopeptidase inhibitors ameliorating recovery from brain trauma |
| 01/13/2005 | WO2005002623A1 Remedy for sarcoidosis and method of treating the same |
| 01/13/2005 | WO2005002612A1 Composition for treating and/or preventing dysfunctions associated with type 2 diabetes mellitus and insulin resistance |
| 01/13/2005 | WO2005002611A1 Formulations for the treatment of arhritis conditions |
| 01/13/2005 | WO2005002602A2 Composition for treating and/or preventing dysfunctions associated with type 2 diabetes mellitus and insulin resistance |
| 01/13/2005 | WO2005002600A2 Composition for treating and/or preventing dysfunctions associated with type 2 diabetes mellitus |
| 01/13/2005 | WO2005002599A1 Buffered compositions for dialysis |
| 01/13/2005 | WO2005002597A1 Method for delivering polymerized therapeutic agent compositions and compositions thereof |
| 01/13/2005 | WO2005002593A1 Aivlosin for the treatment of disease due to brachyspira pilosicoli or ornithobacterium rhinotracheale |
| 01/13/2005 | WO2005002592A2 Stable oral compositions of azithromycin monohydrate |
| 01/13/2005 | WO2005002591A1 Treatment psoriasis, impetigo, tinea by lipositol, cephalin and lecithin |
| 01/13/2005 | WO2005002590A1 Agent inducing increase in bone mass |
| 01/13/2005 | WO2005002589A1 Improvement of the hatching ability of egg-laying animals |
| 01/13/2005 | WO2005002588A1 Enteric coated composition comprising prostaglandin analogs as chloride channel opener |
| 01/13/2005 | WO2005002587A1 Quetiapine metabolite with antipsychotic activity |
| 01/13/2005 | WO2005002586A1 Metabolite of quetiapine |
| 01/13/2005 | WO2005002585A1 Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor |
| 01/13/2005 | WO2005002584A1 Use of roscovitine for treating lymphocytic leukemia |
| 01/13/2005 | WO2005002583A1 Use of thieno`2,3-d ! pyrimidines for the prophylaxis or treatment of hyperactivity disorder |
| 01/13/2005 | WO2005002582A2 Trp-p8 active compounds and therapeutic treatment methods |
| 01/13/2005 | WO2005002581A1 Use of osmolytes obtained from extremophilic bacteria for producing medicaments for the external treatment of neurodermatitis |
| 01/13/2005 | WO2005002580A1 Use of brimonidine for preventing and reducing the severity of stress-associated conditions |
| 01/13/2005 | WO2005002579A1 Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors |
| 01/13/2005 | WO2005002578A1 Compositions containing a serotonin selective reuptake inhibitor and a 5-ht2a receptor antagonist |
| 01/13/2005 | WO2005002577A1 Dual nk1/nk3 antagonists for treating schizophrenia |
| 01/13/2005 | WO2005002576A2 Imidazole derivatives and their use as protein kinases inhibitors |
| 01/13/2005 | WO2005002574A1 Pyrazolidinedione derivatives and their use as platelet aggregation inhibitors |
| 01/13/2005 | WO2005002573A2 Methods for using modulators of proline-rich tyrosine kinase 2 |
| 01/13/2005 | WO2005002572A2 Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases |
| 01/13/2005 | WO2005002571A1 Use of aurora kinase inhibitors for reducing the resistance of cancer cells |
| 01/13/2005 | WO2005002570A1 Use of an aziridino compound to selectively inactivate parasites in biological compositions |
| 01/13/2005 | WO2005002569A1 Pellet preparation of ranitidine |
| 01/13/2005 | WO2005002568A1 The application of l-n-butylphthlide in preventing and treating dementia |
| 01/13/2005 | WO2005002567A1 Use of alpha-ketoglutaric acid for the treatment of malnutrition or high plasma glucose condition |
| 01/13/2005 | WO2005002566A1 Antipyretic medicine containing dexibuprofen as an effective component |
| 01/13/2005 | WO2005002565A1 (-)-hydroxycitric acid for controlling inflammation |
| 01/13/2005 | WO2005002564A1 Curing and prophylactic agent applied during the use of alcohol and psychoactive substances |
| 01/13/2005 | WO2005002563A2 Method for treating alcoholic hepatitis |
| 01/13/2005 | WO2005002562A1 The combination of a serotonin reuptake inhibitors and agomelatine |
| 01/13/2005 | WO2005002561A1 Antifungal agent composition for external use |
| 01/13/2005 | WO2005002560A1 Use of alverine, alone or in combination with a tricyclic antidepressant or an antidepressant which is a specific inhibitor of serotonin reuptake for treatment of depression |
| 01/13/2005 | WO2005002559A2 Methods of inhibiting vascular permeability and apoptosis |
| 01/13/2005 | WO2005002558A1 Preventive and/or therapeutic agent for inflammatory bowel disease |
| 01/13/2005 | WO2005002556A1 Use of osmolytes obtained from extremophilic bacteria for the production of inhalable medicaments for the prophylaxis and treatment of pulmonary and cardiovascular diseases and an inhalation device comprising an osmolyte as active agent component |
| 01/13/2005 | WO2005002555A2 Sirt1 modulators for manipulating cell/organism lifespan/stress response |
| 01/13/2005 | WO2005002554A2 A method of promoting sleep using topical administration of vasoactive agents |
| 01/13/2005 | WO2005002553A2 Fluconazole capsules with improved release |
| 01/13/2005 | WO2005002552A2 Benzimidazole derivatives and their use as protein kinases inhibitors |
| 01/13/2005 | WO2005002551A2 Vanilloid receptor (vr) 1 inhibitors for treatment of human immunodeficiency virus (hiv)-mediated pain states |
| 01/13/2005 | WO2005002549A1 Parathyroid hormone (pth) containing pharmaceutical compositions for oral use |
| 01/13/2005 | WO2005002548A1 Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivatives |
| 01/13/2005 | WO2005002546A1 Stabilized topotecan liposomal composition and methods |
| 01/13/2005 | WO2005002545A1 Method of treating acute coronary syndromes |
| 01/13/2005 | WO2005002543A1 Composition and method for the treatment of water related ear disorders |
| 01/13/2005 | WO2005002541A2 Process for preparing formulations of lipid-regulating drugs |
| 01/13/2005 | WO2005002540A2 Dry powder pharmaceutical suspension compositions of cefuroxime axetil |
| 01/13/2005 | WO2005002528A2 Method for treating diabetes |
| 01/13/2005 | WO2005002525A2 Cox-2 and faah inhibitors |
| 01/13/2005 | WO2005002524A2 COMPOUNDS, COMPOSITIONS AND THERAPEUTIC USES OF OLEOYLETHANOLAMIDE-LIKE COMPOUNDS AND MODULATORS OF PPARα |
| 01/13/2005 | WO2005002522A2 Compositions and methods for treating tissue ischemia |
| 01/13/2005 | WO2005002520A2 Ophthalmic compositions for treating ocular hypertension |
| 01/13/2005 | WO2005002519A2 Amphiphilic pyridinium compounds, method of making and use thereof |
| 01/13/2005 | WO2005002518A2 Methods for treating and preventing cardiac arrhythmia |
| 01/13/2005 | WO2005002508A2 Macromolecular platinum chelates |
| 01/13/2005 | WO2005002506A2 Method for treating diseases using hsp90-inhibiting agents in combination with antimetabolites |
| 01/13/2005 | WO2005002495A2 Use of plasma membrane calcium atpase (pmca) inhibitors for inhibiting sperm mobility |
| 01/13/2005 | WO2005002482A1 Transdermal hormone delivery system: compositions and methods |
| 01/13/2005 | WO2005002367A1 Compositions and food products from oat |
| 01/13/2005 | WO2005002337A1 Disinfectant compositions and methods |